COMPREHENSIVE cANCER PROFILING
Epic Sciences’ revolutionary Comprehensive Cancer Profiling detection platform begins with a single, non-invasive blood draw. From this sample, we conduct multiparametric, single cell analysis of protein expression, cell morphology and single cell genomics to see the widest biological range of cells with unmatched sensitivity.
Click on a data point to display its corresponding image.
PROCESS: Comprehensive Cancer Profiling provides a unique, interactive 3D model of the cell population, enabling detailed analysis and identification of cells other technologies might miss.
This unique, proprietary insight enables Epic Sciences tests to deliver the clarity needed to make the most effective therapy decisions – personal, proven and precise.
SINGLE CELL circulating tumor cell Analysis
SINGLE CELL ANALYSIS IS ESSENTIAL TO DETECTING AND UNDERSTANDING CANCER HETEROGENEITY
We can perform single cell genomic profiling of CTC, ctDNA, and immune cell and pair the genomics to distinct digital pathology features or protein markers expressed allowing us to see both cell phenotype and genotype.
Comprehensive Cancer Profiling analyzes all nucleated cells within a blood sample at single cell resolution. Cells from a patient’s blood sample are deposited on glass slides and compared for morphological features, biomarker expression and nuclear integrity, using immunofluorescent staining. Cell phenotype, Biomarker expression, CTCs, ctDNAs, and immune cells are individually analyzed . Circulating tumor cell DNA is amplified by whole genome amplification (WGA) and analyzed by next-generation sequencing (NGS) for the presence of point mutations, copy number alterations, genome-wide chromosomal instability, ploidy, or genome-wide scarring.
Comprehensive Cancer Profiling also provides additional capabilities in establishing heterogeneity.
WHOLE GENOME COPY NUMBER VARIATION (CNV)
Comprehensive Cancer Profiling platform can characterize CNV and genomic instability in subclonal populations to establish disease heterogeneity, and identify specific oncogene amplification or tumor surpressor deletion, genome-wide.
TARGETED RESEQUENCING ASSAYS
Comprehensive Cancer Profiling platform is capable of detecting CTC sub-clonal populations harboring actionable mutations to monitor sensitivity to targeted therapies through the course of treatment. It can also sequence only genes of interest, focusing only on those that are specific drug targets.